Herbal and Dietary Supplement–Induced Liver Injury

Clinics in Liver Disease

Volumn 21, Issue 1, 2017, Pages 135-149

  de Boer, Ynto S ^a,b   Sherker, Averell H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dietary supplements; Drug induced liver injury; Herbals; Liver; Toxicity

Indexed keywords

ALKALINE PHOSPHATASE; CATECHIN; CHELIDONIUM EXTRACT; CIMICIFUGA RACEMOSA EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; HERBALIFE; HYDROXYCUT; JIN BU HUAN; KAVA EXTRACT; LARREA TRIDENTATA EXTRACT; MENTHA PULEGIUM EXTRACT; OXYELITE PRO; PYRROLIZIDINE; SCUTELLARIA BAICALENSIS EXTRACT; TEUCRIUM CHAMAEDRYS EXTRACT; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; PLANT MEDICINAL PRODUCT;

ACTAEA RACEMOSA; ACUTE LIVER FAILURE; AUTOIMMUNE HEPATITIS; BODY BUILDING; CAMELLIA SINENSIS; CHELIDONIUM; CHOLELITHIASIS; CLINICAL FEATURE; DIET SUPPLEMENT INDUCED LIVER IMJURY; DIET SUPPLEMENTATION; DIETARY SUPPLEMENT INDUCED LIVER INJURY; EPHEDRA SINICA; GERMANDER; HEMOCHROMATOSIS; HEPATIC ENCEPHALOPATHY; HERBAL SUPPLEMENT INDUCED LIVER INJURY; HUMAN; LARREA TRIDENTATA; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDICINAL PLANT; MENTHA PULEGIUM; METABOLITE; NONALCOHOLIC FATTY LIVER; PIPER METHYSTICUM; PRIMARY SCLEROSING CHOLANGITIS; QUALITY CONTROL; REVIEW; SCUTELLARIA BAICALENSIS; VIRUS HEPATITIS; VISCUM ALBUM; WEIGHT REDUCTION; WILSON DISEASE; DIETARY SUPPLEMENT; FEMALE; INCIDENCE; MALE; PATHOPHYSIOLOGY; RISK ASSESSMENT; TOXIC HEPATITIS; UNITED STATES;

CHEMICAL AND DRUG INDUCED LIVER INJURY; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INCIDENCE; MALE; PLANT PREPARATIONS; RISK ASSESSMENT; UNITED STATES;

EID: 84991281195     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2016.08.010     Document Type: Review

References (87)

1. 1 US Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. Available at: http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/ucm148003.htm. Accessed September 19, 2016.
2. 2 Commission on Dietary Supplement Labels. Report of the Commission on Dietary Supplement Labels, 1997, Office of Disease Prevention and Health Promotion, Washington, DC.
3. 3 Dietary supplements: FDA may have opportunities to expand its use of reported health problems to oversee products (GAO-13-244), 2013, Government Accountability Office, Washington, DC.
4. 4 Bailey, R.L., Gahche, J.J., Lentino, C.V., et al. Dietary supplement use in the United States, 2003-2006. J Nutr 141:2 (2011), 261–266.
5. 5 Picciano, M.F., Dwyer, J.T., Radimer, K.L., et al. Dietary supplement use among infants, children, and adolescents in the United States, 1999-2002. Arch Pediatr Adolesc Med 161:10 (2007), 978–985.
6. 6 Radimer, K., Bindewald, B., Hughes, J., et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160:4 (2004), 339–349.
7. 7 Bailey, R.L., Gahche, J.J., Miller, P.E., et al. Why US adults use dietary supplements. JAMA Intern Med 173:5 (2013), 355–361.
8. 8 Foote, J.A., Murphy, S.P., Wilkens, L.R., et al. Factors associated with dietary supplement use among healthy adults of five ethnicities: the Multiethnic Cohort Study. Am J Epidemiol 157:10 (2003), 888–897.
9. 9 Block, G., Jensen, C.D., Norkus, E.P., et al. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr J, 6, 2007, 30.
10. 10 Astin, J.A., Why patients use alternative medicine: results of a national study. JAMA 279:19 (1998), 1548–1553.
11. 11 Nahin, R.L., Barnes, P.M., Stussman, B.J., et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report(18), 2009, 1–14.
12. 12 Geller, A.I., Shehab, N., Weidle, N.J., et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med 373:16 (2015), 1531–1540.
13. 13 Andrade, R.J., Lucena, M.I., Fernandez, M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129:2 (2005), 512–521.
14. 14 Bjornsson, E.S., Bergmann, O.M., Bjornsson, H.K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144:7 (2013), 1419–1425 1425.e1–3; [quiz: e19–20].
15. 15 Navarro, V.J., Barnhart, H., Bonkovsky, H.L., et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 60:4 (2014), 1399–1408.
16. 16 Hillman, L., Gottfried, M., Whitsett, M., et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol 111:7 (2016), 958–965.
17. 17 Dietary Supplement and Nonprescription Drug Consumer Protection Act. Public Law 109-462, 120 Stat 4500, Pub. L. No. 109-462 Stat. 4500 (2006).
18. 18 US Food and Drug Administration. FDA Investigation Summary: Acute Hepatitis Illnesses Linked to Certain OxyElite Pro Products. Available at: http://www.fda.gov/Food/RecallsOutbreaksEmergencies/Outbreaks/ucm370849.htm. Accessed September 19, 2016.
19. 19 US Food and Drug Administration. Iovate Health Sciences USA, Inc: Voluntarily Recalls Hydroxycut-Branded Products. Available at: http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2009/ucm145164.htm. Accessed September 19, 2016.
20. 20 Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community Code relating to medicinal products for human use. Official Journal of the European Union: L136/34; 2004. p. 34–57.
21. 21 Directive 2004/24/EC of the European Parliament and of the Council of 31 March 2004 amending as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community Code relating to medicinal products for human use. Official Journal of the European Union: L183/51; 2004. p. 85–90.
22. 22 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Official Journal of the European Union: L183; 2002. p. 51–57.
23. 23 Roytman, M.M., Porzgen, P., Lee, C.L., et al. Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. Am J Gastroenterol 109:8 (2014), 1296–1298.
24. 24 Bessone, F., Hernandez, N., Sanchez, A., et al. The Spanish-Latin American DILI Network: preliminary results from a collaborative strategic initiative. J Hepatol 58:Suppl 1 (2013), 212–213.
25. 25 Naranjo, C.A., Busto, U., Sellers, E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:2 (1981), 239–245.
26. 26 Garcia-Cortes, M., Lucena, M.I., Pachkoria, K., et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 27:9 (2008), 780–789.
27. 27 Benichou, C., Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11:2 (1990), 272–276.
28. 28 Danan, G., Benichou, C., Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:11 (1993), 1323–1330.
29. 29 Benichou, C., Danan, G., Flahault, A., Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46:11 (1993), 1331–1336.
30. 30 Chalasani, N., Fontana, R.J., Bonkovsky, H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135:6 (2008), 1924–1934 1934.e1–4.
31. 31 Reuben, A., Koch, D.G., Lee, W.M., Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52:6 (2010), 2065–2076.
32. 32 Wai, C.T., Tan, B.H., Chan, C.L., et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 27:4 (2007), 465–474.
33. 33 Suk, K.T., Kim, D.J., Kim, C.H., et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 107:9 (2012), 1380–1387.
34. 34 Medina-Cáliz, I., González-Jiménez, A., Bessone, F., et al. Variations in drug-induced liver injury (DILI) between different prospective DILI registries. Clin Ther, 35(8), 2013, e24.
35. 35 US Food and drug Administration. FDA Uses New Authorities To Get OxyElite Pro Off the Market. Available at: http://blogs.fda.gov/fdavoice/index.php/2013/11/fda-uses-new-authorities-to-get-oxyelite-pro-off-the-market/. Accessed September 19, 2016.
36. 36 Navarro, V.J., Bonkovsky, H.L., Hwang, S.I., et al. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci 58:9 (2013), 2682–2690.
37. 37 Woolf, G.M., Petrovic, L.M., Rojter, S.E., et al. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med 121:10 (1994), 729–735.
38. 38 Stickel, F., Droz, S., Patsenker, E., et al. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol 50:1 (2009), 111–117.
39. 39 Robles-Diaz, M., Gonzalez-Jimenez, A., Medina-Caliz, I., et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther 41:1 (2015), 116–125.
40. 40 Lynch, C.R., Folkers, M.E., Hutson, W.R., Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl 12:6 (2006), 989–992.
41. 41 van de Meerendonk, H.W., van Hunsel, F.P., van der Wiel, H.E., Auto-immuunhepatitis door zilverkaars. Bijwerking van een kruidenextract (Trans.) Autoimmune hepatitis induced by Actaea racemosa. Side affects of an herb extract Ned Tijdschr Geneeskd 153:6 (2009), 246–249 [in Dutch].
42. 42 Cohen, S.M., O'Connor, A.M., Hart, J., et al. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 11:5 (2004), 575–577.
43. 43 Mahady, G.B., Low Dog, T., Barrett, M.L., et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 15:4 Pt 1 (2008), 628–638.
44. 44 Naser, B., Schnitker, J., Minkin, M.J., et al. Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract. Menopause 18:4 (2011), 366–375.
45. 45 Verbitski, S.M., Gourdin, G.T., Ikenouye, L.M., et al. Detection of Actaea racemosa adulteration by thin-layer chromatography and combined thin-layer chromatography-bioluminescence. J AOAC Int 91:2 (2008), 268–275.
46. 46 Larrey, D., Vial, T., Pauwels, A., et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 117:2 (1992), 129–132.
47. 47 Dag, M.S., Aydinli, M., Ozturk, Z.A., et al. Drug- and herb-induced liver injury: a case series from a single center. Turk J Gastroenterol 25:1 (2014), 41–45.
48. 48 De Berardinis, V., Moulis, C., Maurice, M., et al. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 58:3 (2000), 542–551.
49. 49 Lambert, J.D., Kennett, M.J., Sang, S., et al. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 48:1 (2010), 409–416.
50. 50 Bonkovsky, H.L., Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 144:1 (2006), 68–71.
51. 51 Mazzanti, G., Menniti-Ippolito, F., Moro, P.A., et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 65:4 (2009), 331–341.
52. 52 Weinstein, D.H., Twaddell, W.S., Raufman, J.P., et al. SlimQuick - associated hepatotoxicity in a woman with alpha-1 antitrypsin heterozygosity. World J Hepatol 4:4 (2012), 154–157.
53. 53 Church, R.J., Gatti, D.M., Urban, T.J., et al. Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. Food Chem Toxicol 76 (2015), 19–26.
54. 54 Bras, G., Jelliffe, D.B., Stuart, K.L., Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. AMA Arch Pathol 57:4 (1954), 285–300.
55. 55 Wilmot, F.C., Robertson, G.W., Senecio disease or cirrhosis of the liver due to Senecio poisoning. The Lancet 196:5069 (1920), 848–849.
56. 56 Tandon, R.K., Tandon, B.N., Tandon, H.D., et al. Study of an epidemic of venoocclusive disease in India. Gut 17:11 (1976), 849–855.
57. 57 Mohabbat, O., Younos, M.S., Merzad, A.A., et al. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. Lancet 2:7980 (1976), 269–271.
58. 58 Stillman, A.S., Huxtable, R., Consroe, P., et al. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 73:2 (1977), 349–352.
59. 59 Bach, N., Thung, S.N., Schaffner, F., Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 87:1 (1989), 97–99.
60. 60 Ridker, P.M., Ohkuma, S., McDermott, W.V., et al. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 88:4 (1985), 1050–1054.
61. 61 Steenkamp, V., Stewart, M.J., Zuckerman, M., Clinical and analytical aspects of pyrrolizidine poisoning caused by South African traditional medicines. Ther Drug Monit 22:3 (2000), 302–306.
62. 62 Shubat, P.J., Banner, W. Jr., Huxtable, R.J., Pulmonary vascular responses induced by the pyrrolizidine alkaloid, monocrotaline, in rats. Toxicon 25:9 (1987), 995–1002.
63. 63 DeLeve, L.D., Shulman, H.M., McDonald, G.B., Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22:1 (2002), 27–42.
64. 64 Russmann, S., Lauterburg, B.H., Helbling, A., Kava hepatotoxicity. Ann Intern Med 135:1 (2001), 68–69.
65. 65 Stickel, F., Baumuller, H.M., Seitz, K., et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 39:1 (2003), 62–67.
66. 66 From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products–United States, Germany, and Switzerland, 1999-2002. JAMA 289:1 (2003), 36–37.
67. 67 Zhao, P., Wang, C., Liu, W., et al. Causes and outcomes of acute liver failure in China. PLoS One, 8(11), 2013, e80991.
68. 68 Zhao, P., Wang, C., Liu, W., et al. Acute liver failure associated with traditional Chinese medicine: report of 30 cases from seven tertiary hospitals in China∗. Crit Care Med 42:4 (2014), e296–e299.
69. 69 Elinav, E., Pinsker, G., Safadi, R., et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 47:4 (2007), 514–520.
70. 70 Teschke, R., Wolff, A., Frenzel, C., et al. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 32:10 (2012), 1543–1556.
71. 71 Johannsson, M., Ormarsdottir, S., Olafsson, S., Lifrarskadi tengdur notkun a Herbalife (Trans.) Hepatotoxicity associated with the use of Herbalife Laeknabladid 96:3 (2010), 167–172 [in Icelandic].
72. 72 Appelhans, K., Frankos, V., Shao, A., Misconceptions regarding the association between Herbalife products and liver-related case reports in Spain. Pharmacoepidemiol Drug Saf 21:3 (2012), 333–334 [author reply: 5].
73. 73 Appelhans, K., Najeeullah, R., Frankos, V., Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data. Aliment Pharmacol Ther 37:7 (2013), 753–754.
74. 74 Reddy, K.R., Bunchorntavakul, C., Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data–authors' reply. Aliment Pharmacol Ther 37:7 (2013), 754–755.
75. 75 Klontz, K.C., DeBeck, H.J., LeBlanc, P., et al. The role of adverse event reporting in the FDA response to a multistate outbreak of liver disease associated with a dietary supplement. Public Health Rep 130:5 (2015), 526–532.
76. 76 Johnston, D.I., Chang, A., Viray, M., et al. Hepatotoxicity associated with the dietary supplement OxyELITE Pro - Hawaii, 2013. Drug Test Anal 8:3–4 (2016), 319–327.
77. 77 Dara, L., Hewett, J., Lim, J.K., Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 14:45 (2008), 6999–7004.
78. 78 Fong, T.L., Klontz, K.C., Canas-Coto, A., et al. Hepatotoxicity due to Hydroxycut: a case series. Am J Gastroenterol 105:7 (2010), 1561–1566.
79. 79 Linnebur, S.A., Rapacchietta, O.C., Vejar, M., Hepatotoxicity associated with Chinese skullcap contained in Move Free Advanced dietary supplement: two case reports and review of the literature. Pharmacotherapy, 30(7), 2010, 750 258e–62e.
80. 80 Yang, L., Aronsohn, A., Hart, J., et al. Herbal hepatoxicity from Chinese skullcap: a case report. World J Hepatol 4:7 (2012), 231–233.
81. 81 Dhanasekaran, R., Owens, V., Sanchez, W., Chinese skullcap in move free arthritis supplement causes drug induced liver injury and pulmonary infiltrates. Case Reports Hepatol, 2013, 2013, 965092.
82. 82 Haouzi, D., Lekehal, M., Moreau, A., et al. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes. Hepatology 32:2 (2000), 303–311.
83. 83 Sheikh, N.M., Philen, R.M., Love, L.A., Chaparral-associated hepatotoxicity. Arch Intern Med 157:8 (1997), 913–919.
84. 84 Benninger, J., Schneider, H.T., Schuppan, D., et al. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 117:5 (1999), 1234–1237.
85. 85 Kienle, G.S., Grugel, R., Kiene, H., Safety of higher dosages of Viscum album L. in animals and humans–systematic review of immune changes and safety parameters. BMC Complement Altern Med, 11, 2011, 72.
86. 86 Thomassen, D., Slattery, J.T., Nelson, S.D., Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione. J Pharmacol Exp Ther 253:2 (1990), 567–572.
87. 87 Neff, G.W., Reddy, K.R., Durazo, F.A., et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 41:6 (2004), 1062–1064.